Lupin Ltd, the pharmaceutical firm, is in the process of expanding its branded portfolio through the launch of pharmaceutical products. These new products have been filed with the US Food and Drug Administration through its own research or through brand acquisitions.
The drug firm's revenues from the US market increased by 54% to INR 3683 crore for 2013, a jump from INR2393 crore in the previous fiscal year. The brands business' share was at 21% of total US sales while its generic business produced revenues at 79% for 2013.
According to Lupin Managing Director Kamal K Sharma, through its annual report, "The company aims to strengthen its branded portfolio with the launch of additional products developed and filed with the USFDA from its own pipeline as well as through strategic brand acquisitions." He added, "The creation of an advanced bio-technology programme and expansion of a truly global novel drug discovery and development pipeline have added (another) dimension to the company's readiness to reinforce sustainability in the long term."
The company's annual report indicated a Baltimore, MD headquarters. The company is the fifth largest generics manufacturer by number of prescriptions in the US as well as the fastest growing drug firm with a growth rate at 6.3% per annum.
Join the Conversation